UK Approves First GLP-1 Receptor Agonist Tablet for Weight Management
L'essentiel
- The UK's MHRA has approved the first GLP-1 receptor agonist tablet, semaglutide (Wegovy), for weight loss and management.
- This daily pill offers a more convenient alternative to weekly injections for adults with obesity or those overweight with weight-related conditions.
Résumé généré par IA
Pourquoi c'est important
Semaglutide injections (Wegovy) have been effective for weight loss but weekly self-injections can be unpleasant. The UK's MHRA has now approved a daily tablet form of semaglutide.
Representational image
People who've been managing their weight with weekly injections might soon have a far more convenient option. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has today, 11 June 2026, approved the first GLP-1 receptor agonist tablet for weight loss and weight management in the country. The drug is semaglutide — sold under the brand name Wegovy — and this time it comes in pill form, not a needle. Semaglutide injections have been around for a while and have become well-known for their effectiveness in helping people with obesity lose weight. But let's be honest — weekly self-injections aren't exactly pleasant, and that's put some people off. A daily tablet changes that equation considerably.
Who Can Get It?
The tablet has been approved for adults living with obesity, meaning a Body Mass Index of 30 or above. It can also be prescribed to people who are overweight — with a BMI between 27 and 30 — as long as they have at least one weight-related health condition, something like type 2 diabetes or high blood pressure. And as with the injectable version, it's not a standalone fix. Patients will need to pair it with a reduced-calorie diet and increased physical activity.
How the Dosing Works
You start low and build up. The beginning dose is 1.5 mg once daily, and from there it steps up through 4 mg and 9 mg before reaching the maximum of 25 mg. Each dose level requires a minimum of one month before moving up. So this isn't something that kicks in overnight — it's a gradual escalation designed to let the body adjust.
What About People Already on the Injection?
Here's where it gets particularly practical. If you're currently using the 2.4 mg semaglutide injection once a week and you're doing so privately, you don't have to start from scratch. The MHRA has confirmed that patients in that situation can transition directly to the 25 mg daily tablet. No need to step through the lower doses again. It's a straightforward switch — and for many, probably a welcome one.
The MHRA's approval marks the first time a GLP-1 tablet of this kind has been cleared for use in the UK, and it signals a broader shift in how weight management treatment might look in the years ahead. Whether the NHS moves to make it widely available remains to be seen, but the regulatory door is now open.
À surveiller
Perspective IA — des possibilités, pas des certitudes
The NHS may consider making the semaglutide tablet widely available.
Possible · Moyen terme
Questions ouvertes
- Will the NHS make the tablet widely available?
- What will be the cost of the tablet compared to the injection?
- What are the long-term side effects of the tablet form?
